#Ecuador #IntelliGenome #Quito #CRISPR-TB #SIMED

Expanding Tuberculosis Diagnostics in Latin America

In a transformative step for tuberculosis (TB) diagnostics, IntelliGenome, Inc., a pioneer in molecular diagnostics, has appointed SIMED S.A. as the exclusive distributor of its CRISPR-TB™ Blood Test in both Peru and Ecuador. This collaboration marks a significant development in the fight against TB, especially in a region where the disease remains a major public health concern.

The Significance of CRISPR-TB™

The CRISPR-TB™ Blood Test is an innovative approach that detects the presence of cell-free DNA from Mycobacterium tuberculosis in the blood. Unlike traditional diagnostic methods that often rely on sputum samples, this blood-based test offers a far less invasive and potentially more accessible option for patients. With DIGEMID registration approval now secured in Peru, IntelliGenome is enhancing its commercial footprint in one of the most critical markets for tuberculosis.

Kurt Wehrle, Vice President of Partnerships and Strategic Alliances at IntelliGenome, expressed confidence in this partnership, stating, "SIMED possesses an in-depth understanding of tuberculosis diagnostics combined with a robust presence in the molecular diagnostics arena, making them the ideal partner for accelerating CRISPR-TB adoption across Peru and Ecuador."

SIMED's Role in the Partnership

Founded in 1985, SIMED S.A. has established itself as a key player in the life sciences sector within Peru and Ecuador. It has developed strong relationships with a vast network of hospitals, reference laboratories, and public health institutions, enabling it to play a pivotal role in enhancing healthcare outcomes in the region. Under the new partnership, SIMED will begin the product registration process for CRISPR-TB™ in Ecuador, extending its reach and contributing significantly to improving tuberculosis diagnostics.

Abelardo Cruces, General Laboratory and Biosciences Business Manager at SIMED, remarked, "The addition of CRISPR-TB to our portfolio is a vital step in strengthening our commitment to provide groundbreaking molecular technologies to clinical laboratories throughout Peru and Ecuador." This statement underscores the shared vision of both organizations toward boosting TB detection and treatment processes.

IntelliGenome's Vision for the Future

IntelliGenome is not just focused on commercial growth; its mission is to advance global healthcare strategies concerning tuberculosis. The CRISPR-TB™ platform, equipped with proprietary molecular detection techniques, is being explored worldwide through collaborations with various clinical, academic, and public health partners. By bolstering both laboratory-based and near-patient testing solutions, IntelliGenome aims to broaden access to effective TB diagnostics that are crucial for early detection and treatment.

As INTELIGENOME strengthens its impactful presence in Latin America, the partnership with SIMED stands as a testament to the potential of innovative technologies in combating public health challenges such as tuberculosis. With CRISPR-TB™, the hope is that faster, more efficient, and less invasive detection will save lives and contribute to curbing the TB epidemic in the region. This collaboration exemplifies a unified effort to leverage modern scientific advancements in the service of health and wellness across communities.

The commitment demonstrated by both companies heralds a new era in tuberculosis care in South America, promising not just improved diagnostic capabilities but a brighter outlook toward eradication efforts against a persistent global health threat.